News | Radiology Business | August 03, 2020

Siemens Healthineers Set to Acquire Varian in $16.4B Deal

Acquisition to create global leader in cancer research and therapeutics and support Siemens Healthineers’ equity story

Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy. Payment of the purchase price of around $16.4 billion is to be enabled by mixed financing from the issuance of new Siemens Healthineers shares and the issuance of bonds. The proceeds from the bonds are to be transferred within the Group to Siemens Healthineers under customary market conditions.

This transaction will enable Siemens to strengthen the competitiveness and independence of Siemens Healthineers. At the same time, Siemens will remain a strong majority shareholder and thus profit from the company’s considerably expanded setup. The transaction is expected to close in the first half of calendar year 2021, subject to approval by Varian shareholders, receipt of regulatory approvals and other customary closing conditions.

“As the first of the three companies in our new Siemens Ecosystem, we gave Siemens Healthineers an independent, focused setup. This approach is the core of our Vision 2020+ strategy, which we’re rigorously executing – even in the time of COVID-19. Therefore, we expressly welcome and support this acquisition since it will be a powerful driver for Siemens Healthineers. A transformational step of this kind wouldn’t have been possible in the conglomerate structure of the old Siemens AG,” said Joe Kaeser, president and CEO of Siemens AG. 

“The acquisition of Varian will create a world-leading company in the area of cancer therapy – a company in which Siemens AG will participate as a strong and long-term majority shareholder,” explained Roland Busch, deputy CEO of Siemens AG. “Siemens Healthineers is excellently positioned in an attractive growth market in the global battle against cancer. The acquisition will benefit everyone – above all patients, but also the shareholders of both companies.”

Transaction conditions 

The transaction underscores the financial strength of the Siemens Group and will be financed by a combination of equity and debt financing. Siemens AG will not participate in the planned equity increase at Siemens Healthineers AG. The additional debt capital is to be borrowed externally by Siemens in the form of bonds and transferred to Siemens Healthineers via intra-Group loans under customary market conditions. Siemens AG aims to maintain its current A+ / A1 rating.

Due to the planned capital increase at Siemens Healthineers AG, in which Siemens AG will not participate, Siemens AG’s stake in Siemens Healthineers AG will decline to about 72 percent from 85 percent. The related increase in the free float of Siemens Healthineers AG will further underscore the company’s independence.

For more information: www.siemens.com

Related Content

JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
Older Americans may be receiving cancer screenings not recommended by the U.S. Preventive Services Task Force, according to Penn State College of Medicine researchers.

Getty Images

News | Radiology Imaging | July 31, 2020
July 31, 2020 — Older Americans may be receiving cancer screenings not recommended by the...
A World Health Organization (WHO) rapid advice guide on the use of chest imaging in the diagnosis and management of COVID-19 was published in the journal Radiology.

Getty Images

News | Coronavirus (COVID-19) | July 30, 2020
July 30, 2020 — A World Health Organization (WHO) rapid advice gui
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
 The Radiological Society of North America (RSNA) has been awarded a $750,000 grant by the Department of Energy’s National Nuclear Security Administration (NNSA) to develop a Global Learning Center (GLC) in Sub-Saharan Africa. The grant will help address the growing need in Sub-Saharan Africa for training in radiology.
News | Radiology Education | July 28, 2020
July 28, 2020 — The Radiological Society of North America (RSNA)
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
Zebra Medical Vision announced its sixth FDA 510(k) clearance for its mammography solution, HealthMammo, which has already received a CE mark. Zebra Medical’s algorithm empowers breast radiologists by prioritizing and identifying suspicious mammograms, providing a safety net for radiologists. The suspicious mammograms are identified faster and read earlier than the current “first-in first-out” standard of care. 
News | Breast Imaging | July 27, 2020
July 26, 2020 —  Zebra Medical Vision announced its sixth FDA 510
(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine latera

(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine lateral sampling (requiring dithering); the filled circles show the data that are sampled without dithering.

News | Computed Tomography (CT) | July 24, 2020
July 24, 2020 — A computed tomography (CT) sca